Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$17.24 USD

17.24
2,127,266

+0.32 (1.89%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $17.25 +0.01 (0.06%) 7:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (97 out of 244)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NextGen (NXGN) Introduces New Integrated Care EHR Solution

by Zacks Equity Research

NextGen's (NXGN) newest solution lends support to comprehensive primary care and behavioral health with intellectual and developmental disabilities.

Zacks Equity Research

STERIS (STE) Hits a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about STERIS (STE) on impressive growth across its operating segments.

Zacks Equity Research

Here's Why You Should Add Bruker (BRKR) Stock to Your Kitty

by Zacks Equity Research

Bruker's (BRKR) Nano Group microelectronics and semiconductor metrology tools continue to perform well on ongoing strength in bookings and backlog.

Zacks Equity Research

AMN Healthcare (AMN) Stock Moves Up 12.9%: What's Driving It?

by Zacks Equity Research

Investors are optimistic about AMN Healthcare's (AMN) strong segmental performance and upbeat first-quarter guidance.

Zacks Equity Research

Here's Why You Should Retain CVS Health (CVS) Stock For Now

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) owing to continued progress in its consumer-centric digital solutions.

Zacks Equity Research

Philips' (PHG) Innovative Product Suite to Cheer Investors

by Zacks Equity Research

Philips (PHG) launches two major cardiological innovations at ACC 2022, adding strength and depth to its existing healthcare portfolio.

Zacks Equity Research

3 Reasons to Retain Accuray (ARAY) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.

Zacks Equity Research

Edwards Lifesciences (EW) Gets FDA Nod for MITRIS RESILIA Valve

by Zacks Equity Research

Edwards Lifesciences' (EW) MITRIS RESILIA valve has been designed to resemble the appearance and function of the native mitral valve.

Zacks Equity Research

Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake

by Zacks Equity Research

Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.

Zacks Equity Research

Cardinal Health (CAH) to Extend Medical Distribution Presence

by Zacks Equity Research

Cardinal Health's (CAH) plans to build a new facility in Columbus, OH, can expand its medical distribution footprint in the region.

Zacks Equity Research

Masimo (MASI) Reports Preliminary Q1 Results, Reiterates '22 View

by Zacks Equity Research

Masimo's (MASI) first-quarter 2022 results are likely to have been dampened by supply chain headwinds.

Zacks Equity Research

Haemonetics' (HAE) Hospital Business Grows, Cost Ails Stay

by Zacks Equity Research

Haemonetics (HAE) has made the NexSys PCS devices available in the United States to ensure timely conversion of the remainder of its major customers to the same by mid-fiscal 2023.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors are optimistic about Hologic's (HOLX) robust international performance and strength in its GYN Surgical business.

Zacks Equity Research

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on strong buoyed by Cologuard volume growth.

Zacks Equity Research

Here's Why You Should Hold on to Glaukos (GKOS) Stock Now

by Zacks Equity Research

Glaukos Corporation (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.

Zacks Equity Research

Omnicell (OMCL) Progresses With Intelligent Infrastructure Tools

by Zacks Equity Research

Omnicell's (OMCL) IVX Station robotic compounding technology apparently supports three times the throughput speed of the current IV robotic technology.

Zacks Equity Research

Here's Why You Should Retain Nevro (NVRO) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.

Zacks Equity Research

LabCorp (LH) Gains From Covance Arm Growth, Cost Pressure Ails

by Zacks Equity Research

LabCorp's (LH) Covance Drug Development arm is benefiting from its collaborations with leading pharmaceutical and biotechnology companies.

Zacks Equity Research

Veeva Systems (VEEV) Sees Wider Adoption of Its Development Cloud

by Zacks Equity Research

Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.

Zacks Equity Research

Zacks.com featured highlights Builders FirstSource, AMN Healthcare Services and PDC Energy

by Zacks Equity Research

Builders FirstSource, AMN Healthcare Services and PDC Energy have been highlighted in this Screen of the Week article.

Zacks Equity Research

Here's Why You Should Retain STERIS (STE) Stock For Now

by Zacks Equity Research

Investors are optimistic about STERIS' (STE) robust segmental performance and upbeat 2022 guidance.

Zacks Equity Research

Thermo Fisher (TMO) Launches NGS Platform for Clinical Labs

by Zacks Equity Research

Thermo Fisher's (TMO) Ion Torrent Genexus Dx Integrated Sequencer makes next-generation sequencing accessible for all clinical laboratories.

Zacks Equity Research

Edwards Lifesciences (EW) Up 7.5% Since Q4 Earnings Release

by Zacks Equity Research

Edwards Lifesciences' (EW) stock rallies on impressive fourth-quarter performance and bullish 2022 guidance.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $106.44 in the latest trading session, marking a +0.88% move from the prior day.

Zacks Equity Research

Philips' (PHG) Lung Suite 3D Imaging Solution Gains Traction

by Zacks Equity Research

Philips' (PHG) innovative lung cancer diagnosis and treatment solution, Philips Lung Suite, is witnessing rapid adoption by clinical partners globally